ES2930077T3 - Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria - Google Patents
Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria Download PDFInfo
- Publication number
- ES2930077T3 ES2930077T3 ES17704039T ES17704039T ES2930077T3 ES 2930077 T3 ES2930077 T3 ES 2930077T3 ES 17704039 T ES17704039 T ES 17704039T ES 17704039 T ES17704039 T ES 17704039T ES 2930077 T3 ES2930077 T3 ES 2930077T3
- Authority
- ES
- Spain
- Prior art keywords
- surgery
- apelin
- subject
- use according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305170 | 2016-02-15 | ||
| PCT/EP2017/053308 WO2017140684A2 (en) | 2016-02-15 | 2017-02-14 | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2930077T3 true ES2930077T3 (es) | 2022-12-07 |
Family
ID=55359484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17704039T Active ES2930077T3 (es) | 2016-02-15 | 2017-02-14 | Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11484577B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3416688B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7063813B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2930077T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017140684A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020180823A1 (en) * | 2019-03-01 | 2020-09-10 | Abrexa Pharmaceuticals, Inc. | Compounds for prevention and treatment of post-operative cognitive dysfunction |
| WO2021222438A1 (en) * | 2020-04-28 | 2021-11-04 | Abrexa Pharmaceuticals, Inc. | Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress |
| WO2023211684A2 (en) * | 2022-04-29 | 2023-11-02 | Noetix Pharma Llc | Prevention and treatment of post-operative cognitive dysfunction (pocd) |
| US20240238333A1 (en) * | 2023-01-12 | 2024-07-18 | Penland Foundation | Treatment of delirium using nitrous oxide |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932667A (en) | 1971-08-02 | 1976-01-13 | Airco, Inc. | Ether compound as an inhalation anesthetic |
| US3954893A (en) | 1971-08-09 | 1976-05-04 | W. R. Grace & Co. | New halogenated cyclobutanes |
| US3987203A (en) | 1973-03-16 | 1976-10-19 | Airco, Inc. | Anesthetizing composition and method |
| DE2340561C2 (de) | 1973-08-10 | 1982-12-16 | Hoechst Ag, 6000 Frankfurt | 2.2.2-Trifluor-1-chloräthyl-äther und Verfahren zu ihrer Herstellung sowie Inhalations-Anästhetikum, das einen dieser Stoffe enthält |
| DE2340560C2 (de) | 1973-08-10 | 1982-12-16 | Hoechst Ag, 6000 Frankfurt | 1.2.2.2-Tetrafluoräthyl-äther, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes Inhalations-Anästhetikum |
| US3987100A (en) | 1974-04-11 | 1976-10-19 | E. I. Du Pont De Nemours And Company | Cyclohexane oxidation in the presence of binary catalysts |
| US3949005A (en) | 1974-05-09 | 1976-04-06 | Airco, Inc. | Hexafluoro-t-butyl-difluoromethyl ether as an inhalation anesthetic |
| US3931344A (en) | 1974-08-22 | 1976-01-06 | W. R. Grace & Co. | Bromofluorocyclopropanes |
| US3932529A (en) | 1974-12-26 | 1976-01-13 | W. R. Grace & Co. | Halocyclopropyl halomethyl ethers |
| US3995062A (en) | 1974-12-26 | 1976-11-30 | W. R. Grace & Co. | Halocyclopropyl halomethyl ethers |
| US3932669A (en) | 1975-01-10 | 1976-01-13 | W. R. Grace & Co. | 1-Chloro-2,2-dimethyl-1,4,4-trifluorocyclobutane as an anesthetics |
| US4220644A (en) | 1976-05-03 | 1980-09-02 | Smithkline Corporation | 7-Acylamino-3-(substituted tetrazolyl thiomethyl) cephalosporins |
| US4281020A (en) | 1979-03-01 | 1981-07-28 | The Dow Chemical Company | Deuterated analogues of methoxyflurane useful as an anesthetic |
| US4346246A (en) | 1979-03-12 | 1982-08-24 | Airco, Inc. | Process for adjusting the halogen content of halogenated aliphatic ethers |
| US4262144A (en) | 1979-10-25 | 1981-04-14 | The Dow Chemical Company | Deuterated isoflurane |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5391579A (en) | 1993-01-28 | 1995-02-21 | University Of Iowa Research Foundation | Deuterated sevoflurane as an inhalational anesthetic |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| CN1283228A (zh) | 1997-12-24 | 2001-02-07 | 武田药品工业株式会社 | 多肽、其生产方法及应用 |
| US7635751B2 (en) | 2000-03-23 | 2009-12-22 | Takada Pharmaceutical Company Limited | Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof |
| US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
| US20050112701A1 (en) | 2003-09-11 | 2005-05-26 | Aventis Pharma Deutschland Gmbh | Test system for the identification of APJ receptor ligands |
| US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| US9308232B2 (en) * | 2006-06-05 | 2016-04-12 | Keyview Labs, Inc. | Compositions and methods for enhancing brain function |
| EP1903052A3 (en) | 2006-07-28 | 2008-04-02 | Faust Pharmaceuticals SA | APJ receptor ligands and uses thereof |
| US20100113570A1 (en) | 2008-04-23 | 2010-05-06 | The General Hospital Corporation | Prevention and treatment of post-operative cognitive dysfunction |
| US8946382B2 (en) | 2009-02-27 | 2015-02-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Apelin peptides and methods of use |
| US20120316247A1 (en) | 2009-10-20 | 2012-12-13 | The General Hospital Corporation | Prevention and treatment of post-operative cognitive dysfunction (pocd) |
| DK2547363T3 (da) * | 2010-02-17 | 2020-09-07 | The Kennedy Trust For Rheumatology Res | Fremgangsmåder til forebyggelse eller behandling af udløste inflammatoriske reaktioner med tumor nekrosis faktor alfa antagonist. |
| EP3780002B1 (en) * | 2010-11-24 | 2024-07-17 | Clinical Ink, Inc. | Systems and methods to assess cognitive function |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| EP3907237A1 (en) | 2012-12-20 | 2021-11-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| AU2014284496A1 (en) | 2013-07-03 | 2016-01-21 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for treating cognitive dysfunction |
| GB201311948D0 (en) | 2013-07-03 | 2013-08-14 | British American Tobacco Co | Curling Machine |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| WO2015013165A1 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic apelin derivatives for the treatment of heart failure |
| WO2015013169A2 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
-
2017
- 2017-02-14 WO PCT/EP2017/053308 patent/WO2017140684A2/en not_active Ceased
- 2017-02-14 US US16/077,949 patent/US11484577B2/en active Active
- 2017-02-14 ES ES17704039T patent/ES2930077T3/es active Active
- 2017-02-14 EP EP17704039.1A patent/EP3416688B1/en active Active
- 2017-02-14 JP JP2018542732A patent/JP7063813B2/ja active Active
-
2022
- 2022-09-27 US US17/935,667 patent/US11896649B2/en active Active
-
2023
- 2023-12-27 US US18/396,828 patent/US20240226238A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019508416A (ja) | 2019-03-28 |
| US20210196798A1 (en) | 2021-07-01 |
| JP7063813B2 (ja) | 2022-05-09 |
| US20230093887A1 (en) | 2023-03-30 |
| US11484577B2 (en) | 2022-11-01 |
| EP3416688A2 (en) | 2018-12-26 |
| EP3416688B1 (en) | 2022-08-17 |
| US11896649B2 (en) | 2024-02-13 |
| WO2017140684A2 (en) | 2017-08-24 |
| WO2017140684A3 (en) | 2017-12-21 |
| US20240226238A1 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11896649B2 (en) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction | |
| Hu et al. | Involvement of the blood–brain barrier opening in cognitive decline in aged rats following orthopedic surgery and high concentration of sevoflurane inhalation | |
| ES2472737T3 (es) | Usos m�dicos adicionales de la proteína antisecretora | |
| ES2834598T3 (es) | Histatina para la curación de heridas corneales y enfermedades de la superficie ocular | |
| KR20200143407A (ko) | Cgrp를 억제하는데 사용하기 위한 신경독소 | |
| JP2019059730A (ja) | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン | |
| PT2371865T (pt) | ANTICORPOS QUE SE LIGAM À FOSFATASE TIROSINA DE PROTEÍNAS HUMANA BETA (FTPH-ß) E SUAS UTILIZAÇÕES | |
| ES2653734T3 (es) | Inhibidores de apoptosis y usos de los mismos | |
| ES2702333T3 (es) | Dispositivos para la médula espinal para promover la regeneración axonal | |
| ES2827184T3 (es) | Métodos de prevención o tratamiento de reacciones inflamatorias desencadenadas utilizando antagonista alfa del factor de necrosis tumoral | |
| KR20150109386A (ko) | 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체 | |
| CN108472332B (zh) | 用于通过经鼻施用来治疗中风的组合物 | |
| ES2210829T3 (es) | Composicion y proceso inmunologico utilizados para modificar transitoriamente la melina del sistema nervioso central de mamiferos para estimular la regeneracion neuronal. | |
| KR20240034761A (ko) | Glp-1r 효능제를 포함하는 약제학적 조성물 | |
| US9873724B2 (en) | Pro-angiogenic peptides and peptide conjugates | |
| ES2247329T3 (es) | Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales. | |
| ES2842523T3 (es) | Métodos y composiciones para el tratamiento de la artritis | |
| ES2988478T3 (es) | Agente profiláctico y/o terapéutico para la demencia | |
| ES2427932T3 (es) | Remedio para la degeneración de los discos intervertebrales | |
| CN113288904B (zh) | Mitoquinone在制备预防和/或治疗运动损伤的药物中的应用 | |
| ES3041501T3 (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder | |
| TWI611805B (zh) | 用於治療坐骨神經損傷之醫藥組合物 | |
| CN118490681B (zh) | 瑞香素在制备治疗淋巴回流障碍的药物中的应用 | |
| CN112274644A (zh) | 一种用于治疗脊柱与骨关节病变并减轻其疼痛的药物 | |
| WO2011021832A2 (ko) | 척수 손상 예방 또는 치료용 조성물 |